4D-150 for Age-Related Macular Degeneration
(4FRONT-2 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called 4D-150 for individuals with age-related macular degeneration (AMD), a condition that affects vision. The researchers aim to determine if 4D-150 can manage this condition more effectively than the existing treatment, aflibercept, an injection used for AMD. Participants should have an AMD diagnosis and either have never received certain eye injections or have had only a minimal number. This trial targets those who have shown some improvement with past treatments but still exhibit active signs of the disease. As a Phase 3 trial, it represents the final step before FDA approval, offering participants the opportunity to contribute to a potentially groundbreaking treatment.
Do I need to stop my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. However, it does mention that you cannot have glaucoma requiring more than 2 topical medications for control.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Studies have shown that 4D-150 is generally safe for patients. Earlier research found no serious side effects and no eye swelling, suggesting that 4D-150 is safe for use in the eye. This is promising for treating age-related macular degeneration. While encouraging, the current trial will provide more information about its safety and effectiveness.12345
Why do researchers think this study treatment might be promising?
Researchers are excited about 4D-150 for age-related macular degeneration because it uses a novel gene therapy approach. While most treatments like Aflibercept work by inhibiting VEGF proteins to slow vision loss, 4D-150 delivers genetic material directly into the eye to potentially provide a longer-lasting effect. This could mean fewer injections and more sustained results for patients, making it a promising alternative to current therapies.
What evidence suggests that this trial's treatments could be effective for age-related macular degeneration?
Research shows that 4D-150, which participants in this trial may receive, has promising results for treating age-related macular degeneration (AMD), especially the wet type. Studies have found that 4D-150 can help maintain clear and stable vision over time. It also reduces the need for additional injections, offering more convenience and comfort for patients. The treatment steadily releases a protein that reduces abnormal blood vessel growth in the eye, aiding in managing wet AMD symptoms. Overall, past research indicates that 4D-150 has been well-tolerated, with no significant eye inflammation reported.36789
Who Is on the Research Team?
Julie Tsai, MD
Principal Investigator
4D Molecular Therapeutics
Are You a Good Fit for This Trial?
Adults over 50 with macular neovascularization due to age-related macular degeneration (nAMD) can join. They must have a certain level of vision and retina thickness, and either be new to treatment or had up to four prior injections with documented improvement. Excluded are those with other causes for MNV, recent major illness/surgery, uncontrolled blood pressure, or history of heart/stroke events within the last 6 months.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single intravitreal injection of 4D-150 or Aflibercept
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- 4D-150
Find a Clinic Near You
Who Is Running the Clinical Trial?
4D Molecular Therapeutics
Lead Sponsor